Kimball Electronics Acquires European-Based Medical CDMO, Helvoet Polymer Technologies B.V.
StockNews.AI · 2 hours
AI Summary
Kimball Electronics announced it acquired Helvoet Polymer Technologies BV for €90 million (~$103 million), at about 9x Helvoet's 2026 adjusted EBITDA. The deal expands Kimball's medical contract manufacturing footprint into Europe and India, with an Indianapolis facility enabling U.S. near-term demand capture and potential program wins from Helvoet's blue-chip customers. A July 1, 2026 conference call will discuss synergies and outlook.
Sentiment Rationale
Material strategic move with accretion potential; multiple expansion likely as the med-CMO platform scales and cross-border synergies materialize.
Trading Thesis
Accretive to FY2027; scaled medical CMO platform could drive multiple expansion in 12–18 months.
Market-Moving
- Expansion into Europe and India could unlock cross-sell with Helvoet clients.
- Acquisition priced at €90m (~$103m), about 9x 2026 adjusted EBITDA.
- Indianapolis facility positions KE to capture near-term U.S. demand.
- July 1 investor call expected to outline synergies and accretion.
Key Facts
- Kimball Electronics to acquire Helvoet Polymer Technologies. Purchase price €90m (~$103m) at ~9x 2026 EBITDA.
- Expands Kimball's medical CMO platform in Europe and India. Indianapolis facility targets near-term U.S. demand.
- Helvoet serves blue-chip medical customers; synergy potential and expanded program wins foreseen.
- Management to host July 1, 2026 conference call to discuss synergies and outlook.
Companies Mentioned
- Kimball Electronics, Inc. (KE): Acquiring Helvoet expands KE's global medical CMO platform; accretive to FY2027.
- Helvoet Polymer Technologies B.V. (Private): European/CDMO with microfluidics focus; will join Kimball, adding Europe/India capacity.
M&A
M&A activity expanding a medical CMO platform within the EMS/CMO sector; aligns with growth strategy to globalize medical manufacturing capabilities.